What question did this study set out to answer?

This perspective aims to explore the effectiveness of weight loss and OSA therapy in managing cardiometabolic risk in patients with obesity-related OSA.

April 27, 2026Open Access

Perspective - Weight loss, OSA therapy, or both for cardiometabolic risk in obesity-related OSA?

Puntos clave

This perspective aims to explore the effectiveness of weight loss and OSA therapy in managing cardiometabolic risk in patients with obesity-related OSA.
Discussion of recent clinical trials on weight loss and its effects on OSA severity.
Analysis of FDA-approved weight loss medications for OSA treatment.
Consideration of management strategies for optimizing outcomes in obesity and OSA.
Clinical trials indicate significant weight loss leads to improved OSA severity.
The FDA has approved a medication specifically for weight loss in OSA treatment.
Ongoing debates address which management strategies yield optimal real-world outcomes.

Resumen

Abstract The emergence of potent and durable obesity pharmacotherapies has the potential to drastically alter the treatment landscape for comorbid obesity and OSA. Recent clinical trials examining the impact of weight loss on OSA have demonstrated marked improvements in both weight and OSA severity, leading to the first FDA approval of a weight loss medication for OSA. However, several questions remain unanswered regarding which trial and management strategies will best optimize real-world outcomes for patients with comorbid obesity and OSA in an equitable manner.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Nokes et al. (Thu,) studied this question.

synapsesocial.com/papers/69eefd64fede9185760d4203 https://doi.org/https://doi.org/10.1093/sleep/zsag116

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo